Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michael Siani-Rose"'
Autor:
Jean-Christophe Quillet, Michael Siani-Rose, Robert McKee, Bonni Goldstein, Myiesha Taylor, Itzhak Kurek
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Autism spectrum disorder (ASD) is a neurodevelopmental condition impacting behavior, communication, social interaction and learning abilities. Medical cannabis (MC) treatment can reduce clinical symptoms in individuals with ASD. Cannabis-res
Externí odkaz:
https://doaj.org/article/26f26e337e65469099a1eb0fde74671e
Autor:
Michael Siani-Rose, Stephany Cox, Bonni Goldstein, Donald Abrams, Myiesha Taylor, Itzhak Kurek
Publikováno v:
Cannabis and Cannabinoid Research. 8:126-137
Autor:
Michael Siani-Rose, Robert McKee, Stephany Cox, Bonni Goldstein, Donald Abrams, Myiesha Taylor, Itzhak Kurek
Publikováno v:
Cannabis and Cannabinoid Research.
Autor:
Michael, Siani-Rose
Publikováno v:
Regenerative Medicine. 1:841-846
Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at tw
Autor:
Michael Siani-Rose
Publikováno v:
Pharmaceuticals, Policy and Law. 12:147-149
Anginera is an epicardial patch developed on the basis of Dermagraft, another FDA-approved product. The underlying principle is that the fibroblasts are cells which can attach and stretch across spaces thus creating a human tissue. Retained in a natu
Autor:
Gail K. Naughton, Stuart K. Williams, Michael Siani-Rose, Gianine M. Figliozzi, Robert S. Kellar
Publikováno v:
Tissue engineering. Part A. 17(17-18)
The current study's purpose was to evaluate the safety and biological effect of a scaffold-based three-dimensional human dermal fibroblast culture (3DFC, also known as Anginera™) to treat chronically ischemic canine hearts. It was hypothesized that